Search Results - "Gutierrez‐Barrera, Angelica M."

Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system by Fouad, Tamer M, MD, Barrera, Angelica M Gutierrez, MS, Reuben, James M, PhD, Lucci, Anthony, MD, Woodward, Wendy A, MD, Stauder, Michael C, MD, Lim, Bora, MD, DeSnyder, Sarah M, MD, Arun, Banu, MD, Gildy, Babiera, MD, Valero, Vicente, MD, Hortobagyi, Gabriel N, MD, Ueno, Naoto T, Dr

“…Summary In the absence of histological criteria that distinguish between inflammatory and non-inflammatory breast cancer, diagnosis of inflammatory breast…”
Get full text

Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience by ARUN, Banu, BAYRAKTAR, Soley, ALBARRACIN, Constance, LIU, Diane D, GUTIERREZ BARRERA, Angelica M, ATCHLEY, Deann, PUSZTAI, Lajos, LITTON, Jennifer Keating, VALERO, Vicente, MERIC-BERNSTAM, Funda, HORTOBAGYI, Gabriel N

“…To compare the pathologic complete response (pCR) rate and relapse-free survival (RFS) and overall survival (OS) after neoadjuvant systemic chemotherapy (NST)…”
Get full text

Simplifying clinical use of the genetic risk prediction model BRCAPRO by Biswas, Swati, Atienza, Philamer, Chipman, Jonathan, Hughes, Kevin, Barrera, Angelica M. Gutierrez, Amos, Christopher I., Arun, Banu, Parmigiani, Giovanni

“…Health care providers need simple tools to identify patients at genetic risk of breast and ovarian cancers. Genetic risk prediction models such as BRCAPRO…”
Get full text

Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer by Layman, Rachel M., Lin, Heather, Gutierrez Barrera, Angelica M., Karuturi, Meghan S., Yam, Clinton, Arun, Banu K.

“…Background BRCA‐associated breast cancers tend to have distinctive features compared to sporadic breast cancers; further characterization can aid in optimizing…”
Get full text

Association between weight gain during adjuvant chemotherapy for early‐stage breast cancer and survival outcomes by Schvartsman, Gustavo, Gutierrez‐Barrera, Angelica M., Song, Juhee, Ueno, Naoto T., Peterson, Susan K., Arun, Banu

“…Obese and overweight women have an increased risk of breast cancer and worse outcomes at the time of diagnosis. Women tend to gain weight after breast cancer…”
Get full text

Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing by Murphy, Brittany L., Yi, Min, Arun, Banu K., Gutierrez Barrera, Angelica M., Bedrosian, Isabelle

“…Background An increasing number of breast cancer patients are undergoing expanded genetic testing and are being identified as germline mutation carriers. We…”
Get full text

Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO by Biswas, Swati, Tankhiwale, Neelam, Blackford, Amanda, Barrera, Angelica M. Gutierrez, Ready, Kaylene, Lu, Karen, Amos, Christopher I., Parmigiani, Giovanni, Arun, Banu

“…The BRCAPRO model estimates carrier probabilities for the BRCA1 and BRCA2 genes, and was recently enhanced to use estrogen receptor (ER) and progesterone…”
Get full text

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells by ARUN, BANU, AKAR, UGUR, GUTIERREZ-BARRERA, ANGELICA M, HORTOBAGYI, GABRIEL N, OZPOLAT, BULENT

“…PARP inhibitors are considered promising anti-cancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring…”
Get full text

Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing by Murphy, Brittany L., Yi, Min, Gutierrez Barrera, Angelica M., Tripathy, Debu, Hunt, Kelly K., Arun, Banu K.

“…Background Women with a history of breast cancer (BC) more commonly have a diagnosis of other primary malignancies (OPMs) than the general population. This…”
Get full text

Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing by Elsayegh, Nisreen, Barrera, Angelica M Gutierrez, Muse, Kimberly I, Lin, Heather, Kuerer, Henry M, Helm, Monica, Litton, Jennifer K, Arun, Banu K

“…The authors retrospectively aimed to determine which of the following three scenarios, related to DCIS entry into BRCAPRO, predicted BRCA mutation status more…”
Get full text

Early onset HER2‐positive breast cancer is associated with germline TP53 mutations by Melhem‐Bertrandt, Amal, Bojadzieva, Jasmina, Ready, Kaylene J., Obeid, Elias, Liu, Diane D., Gutierrez‐Barrera, Angelica M., Litton, Jennifer K., Olopade, Olufunmilayo I., Hortobagyi, Gabriel N., Strong, Louise C., Arun, Banu K.

“…BACKGROUND: Germline TP53 mutations predispose to early onset breast cancer in women and are associated with Li‐Fraumeni syndrome. Published data on the…”
Get full text

Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer by Karakas, Cansu, Francis, Ashleigh M., Ha, Min Jin, Wingate, Hannah F., Meena, Richard A., Yi, Min, Rasaputra, Komal S., Barrera, Angelica M. Gutierrez, Arun, Banu, Do, Kim-Anh, Sahin, Aysegul, Keyomarsi, Khandan, Hunt, Kelly K.

“…BACKGROUND:Pathologic complete response (pCR) has been shown to be associated with favorable outcomes in breast cancer. Predictors of pCR could be useful in…”
Get full text

Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences by Makhnoon, Sukh, Gutierrez Barrera, Angelica M., Bassett, Roland, Afrough, Aimaz, Bedrosian, Isabelle, Arun, Banu K.

“…Background. Patients with unilateral breast cancer carrying pathogenic variants in BRCA1/2 have the option to undergo contralateral prophylactic mastectomy…”
Get full text

Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors by KWON, Janice S, GUTIERREZ-BARRERA, Angelica M, YOUNG, Diana, SUN, Charlotte C, DANIELS, Molly S, LU, Karen H, ARUN, Banu

“…Every year approximately 25% of women diagnosed with breast cancer are younger than 50 years of age, and almost 10% of them have a BRCA mutation. Not all…”
Get full text

High incidence of germline BRCA mutation in patients with ER low‐positive/PR low‐positive/HER‐2 neu negative tumors by Sanford, Rachel A., Song, Juhee, Gutierrez‐Barrera, Angelica M., Profato, Jessica, Woodson, Ashley, Litton, Jennifer Keating, Bedrosian, Isabelle, Albarracin, Constance T., Valero, Vicente, Arun, Banu

“…BACKGROUND The 2015 National Comprehensive Cancer Network guidelines recommend that genetic counseling and germline BRCA mutation testing be offered to women…”
Get full text

Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer by Cohen, Evan N., Fouad, Tamer M., Lee, Bang-Ning, Arun, Banu K., Liu, Diane, Tin, Sanda, Gutierrez Barrera, Angelica M., Miura, Toshihide, Kiyokawa, Iwao, Yamashita, Jun, Alvarez, Ricardo H., Valero, Vicente, Woodward, Wendy A., Shen, Yu, Ueno, Naoto T., Cristofanilli, Massimo, Reuben, James M.

“…Purpose The carbohydrate sialyl Lewis X (sLe X ) mediates cell adhesion, is critical in the normal function of immune cells, and is frequently over-expressed…”
Get full text

Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations by Bayraktar, Soley, Zhou, Jade Z, Bassett, Roland, Gutierrez Barrera, Angelica M, Layman, Rachel M, Valero, Vicente, Arun, Banu

“…Germline variations in genes coding for proteins involved in the oxidative stress and DNA repair greatly influence drug response and toxicity. Because BRCA1…”
Get more information

Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue by Arun, Banu K., Gutierrez Barrera, Angelica M., Ueno, Naoto T.

Get full text

BRCA mutations in women with inflammatory breast cancer by Gutierrez Barrera, Angelica M., Fouad, Tamer M., Song, Juhee, Webster, Rachel, Elsayegh, Nisreen, Wood, Anita L., Demir, Atakan, Litton, Jennifer K., Ueno, Naoto T., Arun, Banu K.

“…BACKGROUND Inflammatory breast cancer (IBC) often affects women at a relatively young age. To the authors' knowledge, the rate of BRCA variants among patients…”
Get full text

Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer by Garber, Haven R., Raghavendra, Akshara Singareeka, Lehner, Michael, Qiao, Wei, Gutierrez-Barrera, Angelica M., Tripathy, Debu, Arun, Banu, Ibrahim, Nuhad K.

“…Patients with hereditary mutations in BRCA1 or BRCA2 (gBRCA1/2) and breast cancer have distinct tumor biology, and encompass a predilection for brain…”
Get full text